West Pharmaceutical Services (FRA:WPS) 10-Year Share Buyback Ratio : -0.20% (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is West Pharmaceutical Services 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. West Pharmaceutical Services's current 10-Year Share Buyback Ratio was -0.20%.

FRA:WPS's 10-Year Share Buyback Ratio is ranked better than
83.86% of 446 companies
in the Medical Devices & Instruments industry
Industry Median: -3.9 vs FRA:WPS: -0.20

Competitive Comparison of West Pharmaceutical Services's 10-Year Share Buyback Ratio

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services's 10-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's 10-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

West Pharmaceutical Services 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

West Pharmaceutical Services (FRA:WPS) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

West Pharmaceutical Services 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (FRA:WPS) » Definitions » 10-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

WST:USA WPS:Germany W2ST34:Brazil

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-1147

Website

https://www.westpharma.com

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.